Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.950
-0.010 (-0.51%)
Dec 30, 2025, 12:03 PM EST - Market open
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $266.73 million as of December 30, 2025. Its market cap has decreased by -6.53% in one year.
Market Cap
266.73M
Enterprise Value
190.77M
1-Year Change
-6.53%
Ranking
Category
Stock Price
$1.95
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $266.73M, an increase of 165.51%. That is a compound annual growth rate of 21.48%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 29, 2025 | 268.09M | -7.50% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | 69.35M | -30.96% |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 965.00B |
| Johnson & Johnson | 500.24B |
| AbbVie | 406.46B |
| UnitedHealth Group | 300.58B |
| AstraZeneca | 286.29B |
| Novartis AG | 267.64B |
| Merck & Co. | 265.03B |
| Novo Nordisk | 232.28B |